Biote Corp. Class A Common Stock (BTMD) is a publicly traded Healthcare sector company. As of May 21, 2026, BTMD trades at $2.10 with a market cap of $57.93M and a P/E ratio of 4.28. BTMD moved +6.08% today. Year to date, BTMD is -14.98%; over the trailing twelve months it is -47.24%. Its 52-week range spans $1.27 to $6.98. Analyst consensus is strong buy with an average price target of $2.50. Rallies surfaces BTMD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
BTMD financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. BTMD recently traded at $2.10. Market cap is $57.93M. P/E ratio is 4.28. Revenue is $188.16M.
| Metric | Value |
|---|---|
| Price | $2.10 |
| Market Cap | $57.93M |
| P/E Ratio | 4.28 |
| EPS | $0.49 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.98 |
| 52-Week Low | $1.27 |
| Volume | 8 |
| Avg Volume | 0 |
| Revenue (TTM) | $188.16M |
| Net Income | $18.43M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $192.22M | $31.60M | $0.86 |
| 2024 | $197.19M | $46.00K | $0.09 |
| 2023 | $185.36M | $-2.81M | $0.13 |
| 2022 | $164.96M | $1.32M | $-0.12 |
4 analysts cover BTMD: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $2.50.